Quintiles.com

  • Contact quintiles

    Phone:+1 866 267 4479


    Request a Proposal

  • Therapeutic Expertise Vaccines

  • clinical-trials-header
  • Quintiles Clinical Trial

    In the fight against infectious diseases, vaccine development is a major weapon -- and a significant growth market.

    But you’re often up against tight timelines for executing vaccine trials. How do you minimize start up time and study duration without sacrificing quality? And how can you navigate “me-too” competition and pricing sensitivities in the marketplace?

    Win in vaccine research with the help of an industry leader

    Quintiles has the experience to help you get your vaccine development right. We’ve provided clinical services for more than 150 vaccine trials over the past five years, spanning more than 64 countries and involving 300,000 subjects.

    Our vaccine trials also span diverse indications, including seasonal and pandemic influenza, dengue fever, Japanese encephalitis, malaria and leishmaniasis, as well as cancer vaccines and tropical and neglected diseases. We also specialize in bioterrorism, government and non-profit projects.

    How can our vaccine development experience make a difference for you?

    • Agile, upfront planning and data-driven strategies to address a sliding timeline
    • Innovative delivery models to boost portfolio productivity and differentiation
    • Rapid startup, shorter enrollment and study timelines – exceeding industry benchmarks
    • Global footprint, local presence for custom solutions for your product, nearly anywhere in the world
    • Solutions across the product lifecycle, including market access and commercialization strategies

  • Vaccine Research Insights and Innovation

  • Quintiles Clinical Trails

    Quintiles’ Jason Baumgartner, Life Sciences Consulting Director presented on “Understanding Socio-Economic Drivers to Increase Vaccination Coverage” at the World Vaccine Congress 2011. View presentation

  • Quintiles Clinical Trails

    Ellen Vigdorth discusses the challenges of performing vaccine studies in emerging markets. View video